Skip to main content
EVMN logo

Evommune, Inc.

EVMNNYSEHealthcareBiotechnology

$5.93Today:- (-)

As of Oct 15, 2026 close

Market cap
$214.28M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.64$33.20
Volume (live)
-
Avg. volume (3M)
911.72K

Evommune (EVMN) Income Statement

Evommune reported revenue of $13.00M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 85.7% from $7.00M a year earlier. Evommune posted a net loss of $68.87M, compared with a net loss of $66.81M a year earlier. Gross margin was 100.0% and operating margin -623.6%.

Evommune Income Statement Analysis

Values in millions USD

Scroll to see more
Evommune, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023
Period endingDec 2025Dec 2024Dec 2023
Revenue & Gross Profit
Revenue13.007.005.00
Cost of Revenue0.001.291.00
Gross Profit13.005.715.00
Operating Expenses
Research & Development74.0464.2432.00
Selling, General & Administrative20.0311.4810.85
Operating Expenses94.0775.7342.85
Operating Income-81.07-70.01-37.85
Other Income/Expense
Interest Income3.323.243.86
Interest Expense-0.010.03-0.06
Other Income/Expense12.203.203.80
Income
Income Before Tax-68.87-66.81-34.05
Income Tax Expense0.000.000.00
Net Income-68.87-66.81-34.05
Net Income - Continuous Operations-68.87-66.81-34.05
Net Income - Discontinued Operations---
EBITDA-79.68-65.49-36.85
EBIT-81.07-70.01-37.85
Depreciation & Amortization1.391.291.00
Earnings Per Share
Basic EPS-11.00-2.00-27.00
Diluted EPS-11.00-2.00-27.00
Basic Shares Outstanding6.1430.081.25
Diluted Shares Outstanding6.1430.081.25

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evommune Financial Statements

What was Evommune's revenue in fiscal 2025?

Evommune reported revenue of $13.00M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 85.7% from $7.00M a year earlier.

Is Evommune profitable?

No. Evommune reported a net loss of $68.87M in fiscal 2025. In fiscal 2024 it lost $66.81M.

What is Evommune's operating margin?

Evommune's operating income was −$81.07M on revenue of $13.00M in fiscal 2025, an operating margin of -623.6%, compared with -1000.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition